{
  "schemaVersion": 1,
  "id": "research-185",
  "slug": "185-what-the-volenrelaxin-trial-revealed-about-measuring-congestion",
  "title": "What the Volenrelaxin Trial Revealed About Measuring Congestion",
  "catalogLabel": "Human Relaxin-2",
  "productCollection": "https://heritagebiolabs.com/research-library/products/human-relaxin-2",
  "productHandles": [
    "human-relaxin-2-588",
    "human-relaxin-2-562"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/human-relaxin-2-588",
    "https://heritagebiolabs.com/product/human-relaxin-2-562"
  ],
  "readingFocus": "Methods & identity",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 347,
  "sourceYears": [
    2025
  ],
  "paragraphs": [
    "A peptide is an amino-acid chain held together by peptide bonds. It can act as a hormone, and a modified version can behave differently because of how long it stays in circulation. Human relaxin-2 is the hormone that inspired volenrelaxin, a longer-acting investigational molecule. The phase 2 trial discussed here tested volenrelaxin in people with worsening heart failure and preserved ejection fraction, a condition in which the heart can eject a usual proportion of blood while still having difficulty filling or coping with pressure. The original clinical report was published in 2025 and is the direct source for these findings. [1]",
    "Barry Borlaug and colleagues planned to compare several exposure groups with placebo. They assessed how the left atrium, a chamber of the heart, stretches as it receives blood. The primary outcome was change in a measure called left atrial reservoir strain. Secondary measures included a blood marker that can rise when the heart is under stress and an estimate of kidney filtration. The design let the team ask whether changes in heart mechanics aligned with changes in congestion and kidney function. [1]",
    "A low exposure group showed an improvement on the strain measure compared with placebo. Higher groups did not show the same clear difference on that outcome. When the treatment groups were combined for analysis, the blood marker NT-proBNP increased, and there was no clear improvement in the estimate of kidney filtration. The sponsor stopped the trial early after 332 people had enrolled because of evidence of worsening congestion. The report also described imprecise signals involving hospitalization and serious events, which should not be presented as definite estimates of risk. [1]",
    "This study shows why a result can look encouraging on one measurement while still raising a concern overall. A change in how an atrium stretches is an important observation about one aspect of heart function. It does not settle how a patient feels, how often that patient is hospitalized, or whether congestion improves. The evidence concerns volenrelaxin in this particular group, not unmodified human relaxin-2 or all compounds that activate the same receptor. [1]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Borlaug BA et al. Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial. Nature Medicine (online 2025-08-31).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40887551/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/185-what-the-volenrelaxin-trial-revealed-about-measuring-congestion",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/185-what-the-volenrelaxin-trial-revealed-about-measuring-congestion.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/185-what-the-volenrelaxin-trial-revealed-about-measuring-congestion.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 037 - Hexarelin and Human Relaxin-2.docx",
    "sourceArticleNumber": 185,
    "contentSha256": "b8fe8a8f701cee14ddd17fa7e0654bca2b26b7f4acf3a88a63b35efe62bdddfa",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
